MONTREAL, March 17, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-EU) specialty pharmaceutical company, will release its fourth quarter and year-end 2021 financial results this Thursday, March 24, 2022 before the opening of trading. Marlet. Following this release, Knight will host a conference call and webcast. Knight cordially invites all interested parties to participate in this call.
Dated : Thursday, March 24, 2022
Time : 8:30 a.m. ET
Telephone : Toll free 888-254-3590 or international 1-647-794-4605
Webcast : www.gud-knight.com or by clicking on the link Webcast
This webcast is audio-only. To access the broadcast, Media Player is required.
Retransmission : An archived webcast will be available for 30 days at www.gud-knight.com
About Knight Therapeutics Inc.
Knight Therapeutics Inc., based in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing the rights to distribute innovative pharmaceutical products for the Canadian and Latin American markets . Knight owns Biotoscana Investments SA, a pan-Latin American specialty pharmaceutical company. Knight’s Latin American subsidiaries operate as United Medical, Biotoscana Farma and Laboratorio LKM. The shares of Knight Therapeutics inc. trade on the TSX under the symbol “GUD”. For more information about Knight Therapeutics Inc., visit its website at www.gud-knight.com or www.sedar.com.
Knight Therapeutics Inc. Forward-Looking Statements
This document may contain forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements. Knight Therapeutics Inc. considers that the assumptions on which these forward-looking statements are based are deemed reasonable as of the date they are made, but it warns the reader that these assumptions about future events, many of which are beyond the control of Therapeutics Knight inc. and its affiliates, may prove to be incorrect. Factors and risks that could cause actual results to differ materially from anticipated results are discussed in Knight Therapeutics Inc.’s Annual Report. and in Knight Therapeutics Inc.’s Annual Information Form. for the year ended December 31, 2020 filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statement, whether in response to new information or future events, except as required by law.
